C1M

• Measures degradation fragments of type I collagen resulting from matrix metalloproteinase activity.
• Reflects pathological soft tissue destruction and extracellular matrix remodeling.
• Enables non-invasive monitoring of connective tissue turnover in chronic and progressive diseases.
• Supports evaluation of disease progression in fibrotic, inflammatory, and degenerative disorders.
• Provides quantitative insights into the impact of therapeutic interventions targeting tissue remodeling.
• Applicable for research into mechanisms of fibrosis and extracellular matrix breakdown.
• Facilitates patient stratification and prognosis in studies of tissue-destructive conditions.

The C1M biomarker assay quantifies neo-epitope fragments of type I collagen that are generated through matrix metalloproteinase-driven cleavage, serving as a specific indicator of pathological soft tissue destruction and extracellular matrix remodeling. This non-invasive assay enables dynamic assessment of connective tissue turnover in a range of chronic and progressive diseases, including fibrotic, inflammatory, and degenerative conditions. By capturing changes in type I collagen breakdown, C1M supports research, monitoring of disease progression, and therapeutic development aimed at modulating tissue remodeling processes.

Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.